Susan D’Aloisio

505 total citations
7 papers, 408 citations indexed

About

Susan D’Aloisio is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Susan D’Aloisio has authored 7 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Susan D’Aloisio's work include Cell death mechanisms and regulation (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Prostate Cancer Treatment and Research (2 papers). Susan D’Aloisio is often cited by papers focused on Cell death mechanisms and regulation (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Prostate Cancer Treatment and Research (2 papers). Susan D’Aloisio collaborates with scholars based in Canada, United States and Switzerland. Susan D’Aloisio's co-authors include Anthony W. Tolcher, Martin Gleave, K. N., Nicholas Murray, C. Bryce, Richard Klasa, Eric K. Rowinsky, Karen A. Gelmon, Kim Chi and Ian M. Thompson and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Molecular Cancer Research.

In The Last Decade

Susan D’Aloisio

7 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan D’Aloisio Canada 4 262 140 130 89 38 7 408
K. N. Canada 11 286 1.1× 208 1.5× 213 1.6× 144 1.6× 38 1.0× 21 509
Matthew R. Strickland United States 8 251 1.0× 218 1.6× 150 1.2× 74 0.8× 29 0.8× 18 475
Helen Pak Canada 7 357 1.4× 126 0.9× 111 0.9× 64 0.7× 35 0.9× 7 499
M Kůta Czechia 3 205 0.8× 224 1.6× 152 1.2× 47 0.5× 39 1.0× 5 382
Alexandra Corella United States 8 251 1.0× 161 1.1× 183 1.4× 101 1.1× 29 0.8× 11 438
Raquel Bermudo Spain 10 254 1.0× 121 0.9× 169 1.3× 131 1.5× 17 0.4× 13 425
Robert Tjin Tham Sjin United States 7 219 0.8× 122 0.9× 55 0.4× 61 0.7× 15 0.4× 10 331
Matias Casás‐Selves United States 8 350 1.3× 175 1.3× 71 0.5× 126 1.4× 33 0.9× 9 549
Chanpheng Phommaly United States 4 257 1.0× 164 1.2× 152 1.2× 92 1.0× 78 2.1× 8 364
Yasunobu Kuraishi Japan 9 240 0.9× 138 1.0× 68 0.5× 67 0.8× 18 0.5× 16 429

Countries citing papers authored by Susan D’Aloisio

Since Specialization
Citations

This map shows the geographic impact of Susan D’Aloisio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan D’Aloisio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan D’Aloisio more than expected).

Fields of papers citing papers by Susan D’Aloisio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan D’Aloisio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan D’Aloisio. The network helps show where Susan D’Aloisio may publish in the future.

Co-authorship network of co-authors of Susan D’Aloisio

This figure shows the co-authorship network connecting the top 25 collaborators of Susan D’Aloisio. A scholar is included among the top collaborators of Susan D’Aloisio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan D’Aloisio. Susan D’Aloisio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Borges, Virginia F., Susan D’Aloisio, Emma Barrett, et al.. (2013). Abstract A050: ARRY-380, an oral HER2 inhibitor: Final phase 1 results and conclusions. Molecular Cancer Research. 11(10_Supplement). A050–A050. 2 indexed citations
2.
Chia, Stephen, K.N. Chi, C. Kollmannsberger, et al.. (2007). 706 POSTER A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies. European Journal of Cancer Supplements. 5(4). 109–109. 1 indexed citations
3.
N., K., Christian Kollmannsberger, Katherine Paton, et al.. (2007). A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies. Journal of Clinical Oncology. 25(18_suppl). 3594–3594. 2 indexed citations
4.
Tolcher, Anthony W., Kim Chi, John G. Kuhn, et al.. (2005). A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research. 11(10). 3854–3861. 123 indexed citations
5.
Davis, Alison, Karen A. Gelmon, Lillian L. Siu, et al.. (2003). Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks. Investigational New Drugs. 21(1). 85–97. 78 indexed citations
6.
N., K., Martin Gleave, Richard Klasa, et al.. (2001). A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.. PubMed. 7(12). 3920–7. 156 indexed citations
7.
Gelmon, Karen A., Jean Latreille, Anthony W. Tolcher, et al.. (2000). Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 18(24). 4098–4108. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. N. Breakdown of academic impact, for papers by Matthew R. Strickland Breakdown of academic impact, for papers by Helen Pak Breakdown of academic impact, for papers by M Kůta Breakdown of academic impact, for papers by Alexandra Corella Breakdown of academic impact, for papers by Raquel Bermudo Breakdown of academic impact, for papers by Robert Tjin Tham Sjin Breakdown of academic impact, for papers by Matias Casás‐Selves Breakdown of academic impact, for papers by Chanpheng Phommaly Breakdown of academic impact, for papers by Yasunobu Kuraishi
Rankless by CCL
2026